Tony Hagen

Articles

The Debate Over Early Screening for Pancreatic Cancer Continues

March 8th 2019

Higher costs associated with advanced stage pancreatic cancer, are potentially avoidable with screening and earlier treatment. However, the US Preventive Services Task Force in an ongoing draft review has reaffirmed its stance against screening in asymptomatic individuals.

NCCN Guidelines Gain Traction Around the Globe

March 4th 2019

Global use of cancer management guidelines from the National Comprehensive Cancer Network has climbed rapidly in recent years.

Newer Agents Extend Survival and Reduce Toxicity in CLL

March 4th 2019

New agents in chronic lymphocytic leukemia are significantly strengthening the armamentarium, particularly next-generation BTK and PI3K inhibitors, and although toxicities remain an issue, tolerability may be improving.

AML Management Evolving for Elderly Patients

March 3rd 2019

More options are available than ever before for treating older patients with acute myeloid leukemia and fresh hopes are resting on combinations of venetoclax plus hypomethylating agents.

Watch-and-Wait Approach Can Be Beneficial Strategy in MCL

March 3rd 2019

Prognostic indices for mantle cell lymphoma are good for classifying patients but do little in the way of guiding treatment, and often the best course of action is to watch and wait.

Chemotherapy Poised to Have Minor Role in Future CLL Treatment

March 3rd 2019

The day is approaching that chemotherapy may be unnecessary for the treatment of patients with chronic lymphocytic leukemia.

Making the Case for Earlier CAR T-Cell Therapy in Lymphoma

March 2nd 2019

Real-world data on the use of chimeric antigen receptor T-cell therapy in large B-cell lymphoma bear out the pivotal results from ZUMA-1 and demonstrate not only that the treatment approach is here, but also that it’s time to address issues of efficacy, safety, cost, and moving this approach into earlier lines of therapy.

BCMA-Directed CAR T-Cell Therapy Makes Strong Entrance in Myeloma

March 1st 2019

B-cell maturation antigen-specific chimeric antigen receptor T-cell therapy is delivering impressive results in multiple myeloma, demonstrating durable responses and acceptable toxicities.

Immuno-Oncology Expert Highlights How Steroid Dosage Influences Response

February 9th 2019

Different patterns of response are associated with the dosages of immunosuppressants used to manage the adverse effects of immunotherapies.

CTC Counts Demonstrate Selection Value in Metastatic Breast Cancer

December 6th 2018

The use of circulating tumor-cell counts demonstrated strong value for selecting endocrine therapy versus chemotherapy for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Adjuvant Options Arrive for Melanoma

November 9th 2018

The treatment armamentarium for adjuvant melanoma has expanded rapidly, which has left the treatment challenge of selecting between immunotherapy and targeted therapy without any head-to-head comparative data.

Novel Agents, Earlier Diagnosis Driving Survival Gains in CLL

November 8th 2018

The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis.

Ansell Discusses Combination Potential in Hodgkin Lymphoma

July 20th 2018

Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.

US Versus European Opinions on Upfront Therapy in Hodgkin Lymphoma

July 20th 2018

United States’ versus European perspectives on bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma, along with the value of interim positron emission tomography, were discussed at the 2018 Pan Pacific Lymphoma Conference.

Bleomycin Linked to High Rate of Pulmonary Disorders among Patients with Hodgkin Lymphoma

July 20th 2018

A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.

Treatment Options for CD30-Positive PTCL Subtypes

July 19th 2018

Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.

Navigating the Toxicities of Novel-Novel Combinations in Lymphoma

July 18th 2018

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.

Key Characteristics Emerging for CAR T Cell Success

July 18th 2018

An effective lymphodepletion strategy is critical to success with chimeric antigen receptor T-cell therapy, but also the choice of patients and even the cells used for CAR T cell manufacturing should be made with care.

West Coast Study Rates Cancer Centers by Cost and Quality

July 17th 2018

In a groundbreaking study of costs and quality of cancer care among cancer clinics in the state of Washington, investigators found wide disparity in end-of-life care, suggesting that improvements in cost and quality could be attained if treatment centers share information on what works and endeavor to improve.

Oncology Groups Respond to CMS' Proposals for Payment Cuts

July 14th 2018

The Centers for Medicare & Medicaid Services has proposed a slate of changes that would reduce payment for some forms of patient evaluation and management and reduce the payment margin over wholesale acquisition cost for Medicare Part B drugs.